Borderline Tumors of the Ovary: Clinical Course and Prognostic Factors
| Autor: | Alexander Traut, Friedrich Kommoss, N. Ewald-Riegler, Rita Hils, Annette Fisseler-Eckhoff, Philipp Harter, Andreas du Bois, Oya du Bois |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Cancer Research
medicine.medical_specialty Ovariectomy Antineoplastic Agents Ovary Gynecologic oncology Risk Assessment Systemic therapy Disease-Free Survival Risk Factors Germany Prevalence Humans Medicine Ovarian Neoplasms business.industry Hazard ratio Clinical course Histology Hematology General Medicine Middle Aged Confidence interval Surgery Serous fluid Treatment Outcome medicine.anatomical_structure Oncology Female business |
| Zdroj: | Onkologie. 35:28-33 |
| ISSN: | 1423-0240 0378-584X |
| Popis: | Background: The prognosis in borderline tumors of the ovary (BOT) is generally favorable. However, some patients experience recurrence, and mortalities occur. There is a need to better characterize prognostic factors to be considered for individualized treatment planning. Patients and Methods: The data of 158 consecutive patients who underwent surgery for BOT at a tertiary referral center for gynecologic oncology between 1997 and 2008 were retrospectively analyzed. Results: Most patients had early stage disease, and advanced stages FIGO II/III only occurred in 23.4%. Serous histology was most frequent (68%), followed by mucinous histology (22%). All patients received surgery as initial treatment with no adjuvant systemic therapy. 37 patients (40.7% of the patients under the age of 50) had fertility-sparing surgery (FSS). Recurrent disease occurred in 18 (11.4%) patients, and 4 (2.5%) patients died. Independent risk factors for recurrence were FIGO stages > I (hazard ratio (HR) 37.1; 95% confidence interval (CI) 4.5–155.5), tumor rupture (HR 12.4; 95% CI 1.5–61.5), incomplete staging (HR 5.9; 95% CI 1.6–21.3), and FSS in patients Conclusion: Intraoperative tumor rupture, incomplete staging, and FSS – all influenced by the surgeon – may impose a substantial recurrence risk. Therefore, careful counseling and balancing of risk and benefit are mandatory before therapy is applied, especially if FSS is planned. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|